EA202092666A1 - METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG - Google Patents

METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG

Info

Publication number
EA202092666A1
EA202092666A1 EA202092666A EA202092666A EA202092666A1 EA 202092666 A1 EA202092666 A1 EA 202092666A1 EA 202092666 A EA202092666 A EA 202092666A EA 202092666 A EA202092666 A EA 202092666A EA 202092666 A1 EA202092666 A1 EA 202092666A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
cancer
tizotumab
cdrs
methods
Prior art date
Application number
EA202092666A
Other languages
Russian (ru)
Inventor
Решма Абдулла Рангвала
Эстер С.У. Брейж
Сандра Верплоеген
Ойевале О. Абидойе
Леонардо Виана Никасио
Энтони Као
Шира Гардай
Original Assignee
Генмаб А/С
Мсд Интернешнл Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Генмаб А/С, Мсд Интернешнл Гмбх filed Critical Генмаб А/С
Priority claimed from PCT/US2019/031166 external-priority patent/WO2019217455A1/en
Publication of EA202092666A1 publication Critical patent/EA202092666A1/en

Links

Abstract

Настоящее изобретение относится к антителу к PD-1, содержащему определяющие комплементарность области (CDR) пембролизумаба, в комбинации с конъюгатом антитела и лекарственного средства, который связывается с тканевым фактором (TF), содержащим монометилауристатин E и CDR тизотумаба (например, тизотумаб-ведотином), и их применению в способах лечения рака, такого как рак молочной железы и рак шейки матки. Настоящее изобретение также относится к композициям и наборам, содержащим антитело к PD-1, содержащее CDR пембролизумаба, и конъюгат антитела и лекарственного средства, который связывается с TF, содержащий монометилауристатин E и CDR тизотумаба (например, тизотумаб-ведотин), для применения в лечении рака, такого как рак молочной железы и рак шейки матки.The present invention relates to an anti-PD-1 antibody containing complementarity determining regions (CDRs) of pembrolizumab, in combination with an antibody-drug conjugate that binds to tissue factor (TF) containing monomethyluristatin E and tizotumab CDRs (e.g., tizotumab-vedotin) and their use in methods of treating cancer such as breast and cervical cancer. The present invention also provides compositions and kits comprising an anti-PD-1 antibody containing pembrolizumab CDRs and an antibody-drug conjugate that binds to TF containing monomethyluristatin E and tizotumab CDRs (e.g., tizotumab-vedotin) for use in treatment cancers such as breast cancer and cervical cancer.

EA202092666A 2018-10-31 2019-05-07 METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG EA202092666A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753725P 2018-10-31 2018-10-31
PCT/US2019/031166 WO2019217455A1 (en) 2018-05-07 2019-05-07 Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate

Publications (1)

Publication Number Publication Date
EA202092666A1 true EA202092666A1 (en) 2021-02-20

Family

ID=74855488

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092666A EA202092666A1 (en) 2018-10-31 2019-05-07 METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG

Country Status (1)

Country Link
EA (1) EA202092666A1 (en)

Similar Documents

Publication Publication Date Title
EA202092136A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG
EA201891428A1 (en) COMBINATION OF ANTIBODIES TO PD-1 AND BISPECIFIC ANTIBODIES TO CD20 / CD3 FOR THE TREATMENT OF MALIGNANT TUMOR
MX2020008445A (en) Methods for treating cancer with anti-pd-1 antibodies.
EA201891178A1 (en) Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
EA201691225A1 (en) ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION
CR20200459A (en) Her2-targeting antigen binding molecules comprising 4-1bbl
MX2021010116A (en) Anti-pd-l1 antibody and use thereof.
FI3218005T3 (en) Glycan-interacting compounds and methods of use
EA201992573A1 (en) TREATMENT OF HER2-POSITIVE MALIGNANT NEOPLASMS
MX2019013753A (en) Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations.
MX2020008122A (en) Anti-pd-1 antibodies.
MX2021009041A (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof.
MX2022007790A (en) Therapy for the treatment of cancer.
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
JOP20220070A1 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2021003673A (en) Anti-human vsig4 antibodies and uses thereof.
MX2020011823A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate.
EA202090741A1 (en) CONJUGATES OF ANTIBODY TO TISSUE FACTOR AND DRUG AND THEIR APPLICATION IN TREATMENT OF CANCER
MX2020009111A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate.
MX2023001776A (en) Antibodies against ilt2 and use thereof.
EA202092666A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY TO PD-1 AND ANTIBODY TO TISSUE FACTOR AND A DRUG
MX2021001058A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
MX2021008760A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof.
EA202190734A1 (en) METHODS FOR TREATMENT OF CANCER USING A COMBINATION OF ANTIBODY AGAINST VEGF AND ANTIBODY ANTIBODY AGAINST TISSUE FACTOR-DRUG